Is Myriad Genetics, Inc. (MYGN) halal? Doubtful. Based on AAOIFI screening, Myriad Genetics, Inc. passes the business activity screen but has financial ratios approaching AAOIFI limits with a compliance score of 54/100 (Grade: C+).
MYGN β Is Myriad Genetics, Inc. Halal?
DoubtfulMyriad Genetics, Inc.
$4.31
+0.70%
About Myriad Genetics, Inc.
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, a RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, a RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. In addition, it provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, ADHD, and other mental health conditions. Myriad Genetics, Inc. has a strategic collaboration with Illumina, Inc. and Intermountain Precision Genomics for an offering of germline and somatic tumor testing services. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
Sector: Healthcare Β· Industry: Medical - Diagnostics & Research
Why This Stock Is Doubtful
- Debt is 29.5% of market cap β only 0.5 points below the 30% AAOIFI limit
Stocks are marked Doubtful when financial ratios pass but approach AAOIFI thresholds. Consider consulting a qualified scholar for a definitive ruling.
Shariah Compliance Status
Based on AAOIFI screening standards
Fair
Some financial ratios approaching limits
Business Activity Screen
PassedChecks if the business is involved in prohibited activities (alcohol, gambling, pork, conventional banking, etc.)
Financial Ratio Screen
PassedFinancial ratios must be below AAOIFI thresholds
Compliance History
Doubtfulnow
since Jun 2026
Not Halal
until the change above
Tracked since May 2026. Updates automatically on each re-screen.
Purify Your MYGN Dividends
0.2% non-compliant incomeMYGN has 0.2% prohibited income. Calculate exactly how much of your dividends to donate.
Financial Overview
Market Cap
407.1M
Price
$4.31
Sector
Healthcare
Industry
Medical - Diagnostics & Research
More Healthcare Stocks
Track MYGN and 10,000+ stocks with AI insights
Create your free account to unlock AI-powered compliance analysis, track your portfolio, calculate purification, and get unlimited AAOIFI screening.
Disclaimer: This screening is for informational purposes only and does not constitute financial, legal, or religious advice. Compliance is evaluated using AAOIFI financial standards (debt, deposits, and prohibited income ratios) and publicly available data. Ethical, political, social, or environmental considerations are outside the scope of this screening. Individual scholars and methodologies may differ. Always consult a qualified Islamic finance advisor before making investment decisions.